Skip to main content

Table 3 Incidence and types of acute toxicity.

From: A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer

Toxicity endpoint

Group I

Group II

Leucopenia (grade 1-4)

3 (19%)

4 (27%)

All hematologic (grade 3-4)

2 (12%)

1 (7%)

Neurologic (grade I)

2 (12%)

0

Diarrhea (grade 3-4)

6 (37%)

8 (53%)

Allergic reactions

1 (6%)

6 (40%)

Delay in CT

4 (25%)

7 (47%)

  1. Group I received concurrent cisplatin and group II received concurrent paclitaxel. Two patients in group II had to discontinue treatment in cycles 1 & 2 because of severe allergic reactions.
  2. One patient in group I developed an allergic reaction to metochlorpropramide given as antiemetic.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us